A New Window Into the Immune Cells That Attack the Pancreas

One of the biggest obstacles in developing better treatments for Type 1 diabetes is identifying and tracking the T cells that drive beta cell destruction. These autoreactive T cells are extremely rare—scattered among billions of other immune cells in the bloodstream and inaccessible in the pancreas itself. Without a way to study them directly, researchers have struggled to understand what makes these cells tick and whether new therapies are actually working.

Traditional methods of detecting autoreactive T cells are limited. Blood samples can be stimulated in the lab to reveal some reactive cells, but this approach misses important information about what these cells are doing in the body's tissues, where the real battle over beta cells takes place.

Researchers developed a novel approach using intradermal injection of GAD-Alum—a substance containing glutamic acid decarboxylase (GAD), one of the major autoantigens that trigger T1D autoimmunity. When injected just under the skin, this challenge recruits GAD-specific T cells to accessible locations: the skin itself and nearby lymph nodes.

The technique uses two sampling methods to gather these cells: skin suction blisters (painless suction cups applied to the skin) and ultrasound-guided aspiration of lymph nodes. These are minimally invasive compared to traditional biopsies, making it feasible to repeat sampling over time to track disease progression.

When researchers analyzed cells collected from the injection sites, they made striking discoveries. At the skin injection site itself, up to 70% of T cells were clonally expanded—meaning they were descended from a single cell and likely responding to the injected antigen. Using advanced single-cell RNA sequencing and T cell receptor re-expression, they confirmed that 28% of the expanded clones were indeed GAD-reactive.

In the lymph nodes, the picture was different. Only about 4% of clonally expanded T cells were GAD-reactive, representing approximately 0.08% of all T cells in the node. This demonstrates how rare these cells are even when concentrated in immune-response tissues.

Across both the skin and lymph nodes, GAD-reactive T cells displayed transcription signatures associated with Th1 and Th17 immune responses—inflammatory pathways known to be involved in T1D pathogenesis.

This new technique provides researchers with a powerful tool to study autoreactive T cells in living patients. By enabling direct identification and molecular profiling of these cells in vivo, the method could transform how scientists monitor disease activity and evaluate whether experimental immunotherapies are effective.

The minimally invasive nature of the approach means it could potentially be used repeatedly in research studies and future clinical trials, allowing longitudinal tracking of immune changes over time. This represents a significant step forward in understanding the immunology of Type 1 diabetes and developing more targeted interventions.

Source: JCI insight. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.